Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Universite Bordeaux 2, Bordeaux, France.
Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3.
There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.
有证据表明,在马拉维若(MVC)的压力下,HIV-1 的进化会导致 X4 嗜性变异体和/或 MVC 耐药的 R5 嗜性分离株的选择。然而,在含有 MVC 的方案中发生病毒学失败(VF)的患者中,HIV-1 变异体的病毒动力学仍研究甚少。在这里,我们使用群体序列和超深度测序研究了与核心受体使用和 MVC 治疗前 HIV-1 准种性质有关的 HIV-1 在 MVC 上的 V3 环进化。大多数患者在基线时没有检测到可检测的少数 X4 变体。对嗜性的进化进行了随访,直到发生 VF,并显示了这些患者中病毒进化的三种可能性:预先存在的 X4 变体的出现,具有 V3 环突变的新选择的 R5 变体,或没有选择已知突变的 R5 变体的复制。